NewOrg Management System to Launch Its Biggest Update Ever, Reshaping How Nonprofits Manage Data
Washington, D.C.--(Newsfile Corp. - July 30, 2026) - NewOrg Management System, a cloud-based data and case management platform built for nonprofits, human services organizations, and government programs across the United States and Canada, today announced the largest platform update in the company's history. Beginning August 1, 2026, eight new capabilities will roll out across the platform, spanning artificial intelligence, security, and day-to-day operations. The update includes new AI
Logiciels, Soins de santé et hôpitaux, Logement, Autochtones
2026-07-30 12:00 PM EDT | NewOrg Management System Inc
Bachem Confirms Growth and Expects a Strong Second Half 2026
Bubendorf, Switzerland--(Newsfile Corp. - July 30, 2026) - Ad hoc announcement pursuant to Art. 53 LR Media Release Group sales grew to CHF 326.4 million (+4.3% compared to the prior-year period, +7.3% in local currencies). EBITDA amounted to CHF 82.8 million (-9.0% compared to the prior-year period, -4.2% in local currencies) with a margin of 25.4% (prior-year period: 29.1%).
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-07-30 12:56 AM EDT | Bachem Holding AG
CareRx Announces Q3 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Company's Board of Directors has declared a dividend of CAD$0.022 per outstanding common share of the Company ("Common Shares"), payable on October 8, 2026, to holders of record of Common Shares as of the close of business on Septembe
2026-07-29 6:20 PM EDT | CareRx Corporation
CareRx Reports Results for the Second Quarter of 2026
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today reported its financial results for the second quarter ended June 30, 2026. Highlights for the Second Quarter of 2026 Average Beds Serviced1 increased to 91,719 in Q2 2026 from 90,048 Averag
2026-07-29 6:20 PM EDT | CareRx Corporation
Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study
Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the
Soins de santé et hôpitaux, Santé
2026-07-29 6:00 AM EDT | Adia Med Inc.
Launchit Solutions and Privacy Horizon Partner to Help Canadian Health Tech Companies Build, Govern, and Scale with Confidence
Toronto, Ontario--(Newsfile Corp. - July 28, 2026) - Launchit Solutions and Privacy Horizon today announced a strategic partnership that gives Canadian health tech startups and scale-ups coordinated access to healthcare software development, Canadian cloud infrastructure, data governance, privacy and security readiness, and responsible AI governance. Bringing together more than 40 years of combined experience across healthcare, technology, privacy, cybersecurity, and governance, the partnersh
Technologies, Logiciels, Soins de santé et hôpitaux
2026-07-28 10:00 AM EDT | Launchit Solutions Inc.
NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free drug delivery, today announced the filing of two additional patent applications supporting its current patent portfolio. The new applications focus on high-efficiency spring charging technology and automatic dose-establishment technology. Together with previously announced patent applications relating to the Company's dual-spring
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-27 5:15 PM EDT | NuGen Medical Devices Inc.
TelyRx to Host Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - July 24, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended
Soins de santé et hôpitaux, Santé
2026-07-24 7:35 AM EDT | TelyRx
LDIC Inc. Announces the Termination of the Healthcare Special Opportunities Fund
Toronto, Ontario--(Newsfile Corp. - July 23, 2026) - LDIC Inc. (TSX: MDS.UN) (the "Manager") today announced that it will pursue the termination of the Healthcare Special Opportunities Fund (the "Fund") to be effected in the third quarter of 2026 (the "Termination"), subject to obtaining the necessary approvals from the unitholders and regulatory authorities. The Manager has reviewed the current size of the Fund, its management expense ratio, its po
Services bancaires / financiers, Soins de santé et hôpitaux
2026-07-23 5:01 PM EDT | Healthcare Special Opportunities Fund
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments
Soins de santé et hôpitaux, Santé
2026-07-23 1:01 AM EDT | Cosmo Pharmaceuticals N.V.
medmix Strengthens Profitability and Cash Flow While Advancing Growth and Efficiency Initiatives
Baar, Switzerland--(Newsfile Corp. - July 23, 2026) - Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Ad hoc announcement pursuant to Art. 53 LR Half-Year 2026 Results
Technologies, Construction / bâtiments, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-07-23 12:09 AM EDT | medmix AG
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company
Biotechnologies, Soins de santé et hôpitaux
2026-07-21 9:17 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the sig
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-07-21 12:40 AM EDT | Bachem Holding AG
Richards Group Inc. Announces July 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended July 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on July 31, 2026 and will be payable on August 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-07-20 3:54 PM EDT | Richards Group Inc.
ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into an exclusive worldwide license agreement (the "Agreement") with MOR Research Applications Ltd. ("MOR"), the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. ("Yeda"), for proprietary artificial intelligence-driven live
Technologies, Logiciels, Soins de santé et hôpitaux
2026-07-20 6:00 AM EDT | Alzai Health Corp.
LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading on TSX Venture Exchange
Toronto, Ontario--(Newsfile Corp. - July 17, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce that, further to its news release of April 30, 2026, the Ontario Securities Commission has revoked a cease trade order that had been originally issued against the Company on May 6, 2026. The Company is now current on its continuous disclosure obligations under securities legislation. The Company is now in the process
Soins de santé et hôpitaux, Santé
2026-07-17 6:55 PM EDT | LevelJump Healthcare Corp.